{"id":19943,"date":"2022-11-29T17:56:59","date_gmt":"2022-11-29T12:26:59","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19943"},"modified":"2023-12-11T17:39:52","modified_gmt":"2023-12-11T12:09:52","slug":"pharma-news-astrazeneca-regeneron-tenaya","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya","title":{"rendered":"C4X Discovery and AstraZeneca Signs Deal; FDA Rejects Spectrum\u2019s Poziotinib; Orphan Drug Designation to Tenaya\u2019s Gene Therapy; EC Approves Regeneron\u2019s Libtayo; Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations; Japan Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d4f9d863377\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d4f9d863377\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya\/#C4X_Discovery_Holdings_and_AstraZeneca_Signs_Exclusive_USD_402_Million_Global_License\" >C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya\/#FDA_Rejects_Spectrums_Poziotinib_for_Lung_Cancer\" >FDA Rejects Spectrum\u2019s Poziotinib for Lung Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya\/#FDA_Issues_Complete_Response_Letter_to_Poziotinib_for_Metastatic_NSCLC_Harboring_HER2_Exon_20_Mutations\" >FDA Issues Complete Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya\/#Japan_Approves_Trastuzumab_Deruxtecan_for_Previously_Treated_HER2_Metastatic_Breast_Cancer\" >Japan Approves Trastuzumab Deruxtecan for Previously Treated HER2+ Metastatic Breast Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya\/#EC_Approves_Regenerons_Libtayo_for_Advanced_Cervical_Cancer\" >EC Approves Regeneron\u2019s Libtayo for Advanced Cervical Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya\/#FDA_Starts_Speedy_Review_of_Takedas_Dengue_Vaccine\" >FDA Starts Speedy Review of Takeda\u2019s Dengue Vaccine<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading advgb-dyn-61a77493\" id=\"h-c4x-discovery-holdings-and-astrazeneca-signs-exclusive-usd-402-million-global-license\"><span class=\"ez-toc-section\" id=\"C4X_Discovery_Holdings_and_AstraZeneca_Signs_Exclusive_USD_402_Million_Global_License\"><\/span><strong>C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>C4X Discovery Holdings<\/strong> has signed an exclusive global license with <strong>AstraZeneca <\/strong>worth up to <strong>USD 402 million<\/strong> for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop and market an oral therapy for the treatment of inflammatory and respiratory diseases, with a primary focus on chronic obstructive pulmonary disease (COPD).<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market\">COPD<\/a> is the third leading cause of death in the world, accounting for <strong>3.23 million<\/strong> deaths in 2019. However, it is a preventable and treatable chronic lung disease that affects both men and women worldwide. Abnormalities in the lungs&#8217; small airways cause narrowing, limiting airflow in and out of the lungs, and visible destruction of parts of the lung may be observed. Smoking is a major contributor to COPD.<\/p>\n\n\n\n<p>This is CDXD&#8217;s third significant deal with a major pharma, and it further validates its scientific expertise and strategy. The company will be eligible for <strong>USD 16 million <\/strong>in upfront and pre-clinical payments ahead of the first clinical trial, including <strong>USD 2 million<\/strong> upfront, as well as a potential <strong>USD 385.8 million<\/strong> in clinical development and commercial milestones, as well as tiered mid-single digit royalties upon commercialization.<\/p>\n\n\n\n<p><strong>Sir Mene Pangalos, Executive Vice President, BioPharmaceuticals R&amp;D, AstraZeneca<\/strong> said: \u201cAt AstraZeneca, we are committed to transforming care in respiratory and immune-mediated disease and move beyond symptom control. Our alliance with C4XD adds an important new asset to our portfolio to push the boundaries of science by targeting underlying disease drivers to potentially modify the course of these diseases.\u201d<\/p>\n\n\n\n<p><strong>Dr Clive Dix, CEO of C4XD<\/strong>, added: \u201cDrug Discovery is inherently scientifically complex, and it is through our unique expertise and proprietary cutting-edge technologies that C4XD is yet again proving itself as an exemplar in this field.&nbsp; NRF2 is thought to be a critical but challenging anti-inflammatory target, and I am proud of the work by our team to achieve a broad stable of intellectual property for this programme, leading to our third significant deal with a truly world-renowned industry leader.&nbsp; The COPD market alone is worth close to USD 20 billion and rising. But, more importantly, I know that in AstraZeneca\u2019s hands, with their scientific, technical and commercial expertise, our NRF2 Activator programme has the potential to deliver life changing treatments for the millions of patients suffering with COPD across the world.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-aff93f5c\"><span class=\"ez-toc-section\" id=\"FDA_Rejects_Spectrums_Poziotinib_for_Lung_Cancer\"><\/span><strong>FDA Rejects Spectrum\u2019s Poziotinib for Lung Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Hanmi Pharma<\/strong>, a South Korean company that developed the drug initially, reported that the FDA has sent Spectrum Pharma a complete response letter (CRL) for poziotinib, its pan-HER2 inhibitor for a type of lung cancer. Due to the time difference with the US and the fact that the CRL was disclosed during the US Thanksgiving holiday, Hanmi was the first to report the FDA&#8217;s rejection of the marketing application, according to a Korea Biomedical Review report. Hanmi also wanted to avoid any &#8220;unnecessary misunderstandings&#8221; regarding the timing of the disclosure.<\/p>\n\n\n\n<p><strong>Spectrum <\/strong>is expected to make an announcement later today, but the CRL has been widely anticipated, given that the FDA&#8217;s Oncologic Drugs Advisory Committee (ODAC) voted 9 to 4 against <strong>poziotinib <\/strong>approval in September, stating that the benefits outweigh the risks. Spectrum sought accelerated approval for poziotinib as a second-line treatment for <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-epidemiology-forecast\"><strong>patients with HER2 exon 20 insertion-mutated non-small cell lung cancer (NSCLC)<\/strong><\/a>, but the FDA was unconvinced by the data presented in support of the drug in phase II.<\/p>\n\n\n\n<p>In review documents released ahead of the ODAC meeting, the agency expressed concerns about the drug&#8217;s marginal efficacy in clinical trials, high toxicity rates, and concerns about the dose chosen for study. The objective response rate (ORR) in the <strong>phase II ZENITH20 <\/strong>study was <strong>28%<\/strong>, with a median duration of response of around 5 months, and <strong>12%<\/strong> of patients had to discontinue therapy due to side effects.<\/p>\n\n\n\n<p>The FDA began its standard <strong>10-month<\/strong> review of poziotinib in February, with the PDUFA deadline for a decision falling directly on the Thanksgiving holiday. It also expressed concern about a delay in starting a confirmatory trial of the drug, known as <strong>PINNACLE<\/strong>, which had yet to enroll any patients at the time.<\/p>\n\n\n\n<p>Spectrum has since reported positive results with <strong>poziotinib <\/strong>as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><strong>first-line treatment for HER2 exon 20 insertion-mutated NSCLC<\/strong><\/a>, an aggressive form of lung cancer with no approved treatments. Spectrum acquired the global rights to poziotinib from Hanmi in 2015, excluding Korea and China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-ece297ce\"><span class=\"ez-toc-section\" id=\"FDA_Issues_Complete_Response_Letter_to_Poziotinib_for_Metastatic_NSCLC_Harboring_HER2_Exon_20_Mutations\"><\/span><strong>FDA Issues Complete Response Letter to Poziotinib for Metastatic NSCLC Harboring HER2 Exon 20 Mutations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>FDA\u2019s<strong> Oncologic Drugs Advisory Committee (ODAC)<\/strong> has issued a complete response letter to poziotinib which couldn\u2019t secure approval for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-carcinoma-nsclc-market\"><strong>treatment of metastatic non-small cell lung cancer (NSCLC)<\/strong><\/a> harboring HER2 exon 20 mutations, which was licensed out to the U.S. partner Spectrum Pharmaceuticals. Hanmi Pharmaceutical confirmed its disapproval after ODAC voted<strong> 9-4<\/strong>, stating that the current benefits of the drug did not outweigh its risks.&nbsp;<\/p>\n\n\n\n<p>HER2 exon 20 insertion mutations have shown to be oncogenic trigger gene mutations in metastatic NSCLC. ODAC is an individual department of experts that review and evaluate the safety and efficacy data of oncological drugs existing in clinical trial stages. The committee further reports to FDA; however, the finalized decisions are made by FDA. Further, FDA will take charge of the final decisions by 24th November, as per the Prescription Drug User Fee Act (PDUFA).<\/p>\n\n\n\n<p>\u201cWe are disappointed by the outcome of the ODAC meeting, as patients with NSCLC HER2 exon 20 insertion mutations are in need of additional effective and safe therapies. We plan to carefully evaluate our options for this program as we approach the PDUFA date,\u201d <strong>said Tom Riga, president, and CEO of Spectrum Pharmaceuticals<\/strong>, in a statement. The recommendations of ODAC were followed by an unfavourable statement from the FDA scientist session where most of the reviews about the drug poziotinib were negative and followed by comments such as the drug wasn\u2019t able to deliver meaningful advantage over available therapies and requires an additional analysis. Also, the safety profile of the drug was very weak providing only<strong> 28 percent of overall response rate<\/strong> (ORR).&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-0aef53c7\"><span class=\"ez-toc-section\" id=\"Japan_Approves_Trastuzumab_Deruxtecan_for_Previously_Treated_HER2_Metastatic_Breast_Cancer\"><\/span><strong>Japan Approves Trastuzumab Deruxtecan for Previously Treated HER2+ Metastatic Breast Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Japan\u2019s Ministry of Health, Labor, and Welfare (MHLW) approved fam-trastuzumab deruxtecan (Enhertu) for previously treated HER2 harbouring metastatic breast cancer. The approval came after the data from phase 3&nbsp; DESTINY-Breast03 trial where trastuzumab deruxtecan showed reduction in the risk of disease progression and <strong>death rate by 72% <\/strong>as compared to the data obtained by ado-trastuzumab emtansine. The median progression-free survival (PFS) for patients treated with trastuzumab deruxtecan was unachieved, whereas PFS for T-DM1 was <strong>6.8 months<\/strong>.&nbsp;<\/p>\n\n\n\n<p>\u201cWe are proud of the quality and speed in which we were able to deliver a confirmatory phase 3 trial that demonstrated the superiority of [trastuzumab deruxtecan] in prolonging PFS compared to T-DM1 in patients with previously treated HER2 positive metastatic breast cancer,\u201d <strong>Wataru Takasaki, PhD, executive officer, head of R&amp;D Division in Japan, Daiichi Sankyo<\/strong>, stated in a press release. \u201cThis approval by the MHLW highlights the importance of the conditional approval system in Japan that allows for early approval of medicines to treat serious conditions such as breast cancer.\u201d<\/p>\n\n\n\n<p>Japan approved trastuzumab deruxtecan back in<strong> March 2020<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-positive-breast-cancer-market\"><strong>HER2-positive unresectable or recurrent breast cancer<\/strong><\/a> after prior chemotherapy. However, it limited its use to&nbsp; patients who are refractory or intolerant to standard treatments. The previous approval was based on findings from the phase <strong>2 DESTINY-Breast01 trial<\/strong>.<\/p>\n\n\n\n<p>Previously, AstraZeneca and Daiichi Sankyo Company, Limited confirmed that their drug Trastuzumab was approved for reviewing the<strong> Biologics License Application (BLA) <\/strong>by US FDA and was granted Priority Review. Trastuzumab deruxtecan is a HER2-targeting <strong>antibody drug conjugate (ADC)<\/strong> and a potent drug candidate or treating HER2-positive metastatic breast cancer. The date for Prescription Drug User Fee Act (PDUFA) for trastuzumab deruxtecan. The <strong>Prescription Drug User Fee Act (PDUFA)<\/strong> date for trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive metastatic breast cancer, was set for the second quarter of 2020.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-a5b0f5a8\"><span class=\"ez-toc-section\" id=\"EC_Approves_Regenerons_Libtayo_for_Advanced_Cervical_Cancer\"><\/span><strong>EC Approves Regeneron\u2019s Libtayo for Advanced Cervical Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On November 22, 2022, Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) had approved Libtayo\u00ae (cemiplimab) as monotherapy for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-epidemiology-forecast\"><strong>adult patients with recurrent or metastatic cervical cancer<\/strong><\/a> and disease progression on or after platinum-based chemotherapy. The European Commission (EC) approval of Libtayo was based on global EMPOWER-Cervical 1 trial results demonstrating 12 months overall median survival (OS) for the overall patient population.<\/p>\n\n\n\n<p>The trial was conducted in association with GOG Foundation, Inc. (GOG), the European Network for Gynaecological Oncological Trial groups (ENGOT), and NRG Oncology-Japan. EMPOWER-Cervical 1 was an open-label, multi-center Phase 3 trial evaluating Libtayo monotherapy versus an investigator&#8217;s choice of commonly used <a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-pipeline-insight\"><strong>chemotherapy in patients with recurrent or metastatic cervical cancer<\/strong><\/a> who had progressed on platinum-based chemotherapy. The trial evaluated Libtayo compared to an investigator&#8217;s choice of chemotherapy and enrolled 608 patients across 14 countries, irrespective of PD-L1 expression status or histology.&nbsp;<\/p>\n\n\n\n<p>Earlier, in March 2021, the trial was stopped early based on the highly significant effect of Libtayo on overall survival (OS) among squamous cell carcinoma (SCC) patients following a unanimous recommendation by the Independent Data Monitoring Committee.<\/p>\n\n\n\n<p>Dr. Israel Lowy, Senior Vice President, Translational and Clinical Sciences of Oncology at Regeneron, stated that \u201cLibtayo\u00ae was the first programmed cell death protein (PD)-1 inhibitor to demonstrate significant improvements in survival compared to chemotherapy in a Phase III trial. With this fourth approval from the EC, Libtayo\u00ae can now be extended to appropriate patients in the European Union (EU) with advanced cervical cancer, irrespective of their PD-L1 status or histology\u201d.<\/p>\n\n\n\n<p>Cervical cancer is one of the prominent causes of cancer death in women worldwide. As per the estimate, about 600,000 new Cervical cancer cases are registered yearly, and nearly 350,000 lost their lives due to it.&nbsp; &#8220;Despite recent advancements in the prevention and treatment of cervical cancer, there remain limited options for people with recurrent or metastatic cases,&#8221; said Israel Lowy. However, with the approval of Libtayo, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market\"><strong>advanced cervical cancer treatment<\/strong><\/a> scenario is expected to evolve immensely in the coming years.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-ac381bf2\"><span class=\"ez-toc-section\" id=\"FDA_Starts_Speedy_Review_of_Takedas_Dengue_Vaccine\"><\/span><strong>FDA Starts Speedy Review of Takeda\u2019s Dengue Vaccine<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On November 22, 2022, Takeda announced that the US FDA had accepted and granted priority review of the Biologics License Application (BLA) for TAK-003. <a href=\"https:\/\/www.delveinsight.com\/report-store\/dengue-fever-pipeline-insight\"><strong>Takeda&#8217;s tetravalent dengue vaccine candidate (TAK-003)<\/strong><\/a> is an investigational dengue vaccine candidate. TAK-003 is based on a live-attenuated dengue serotype 2 virus, which provides the genetic \u201cbackbone\u201d for all four vaccine viruses. In the phase 2 clinical trial, TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants in children and adolescents.&nbsp;<\/p>\n\n\n\n<p>The TAK-003 BLA is supported by safety and efficacy data from the pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial, where the dengue vaccine candidate met its primary endpoint by preventing 80.2% of symptomatic dengue cases at 12 months. TAK-003 is being evaluated in the US for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age. Currently, TAK-003 has not been approved by the FDA or any other health authority outside of Indonesia. Gary Dubin, M.D., president of the Global Vaccine Business Unit at Takeda, stated that \u201cIf approved, we believe TAK-003 has the potential to become an important dengue prevention option for healthcare providers, and we continue to be encouraged by our discussions with the FDA,\u201d.&nbsp;<\/p>\n\n\n\n<p>Earlier in October 2022, the CHMP of the European Medicines Agency (EMA) recommended the approval of Takeda\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/dengue-pipeline-insight\"><strong>dengue vaccine candidate<\/strong><\/a>, TAK-003, for the prevention of dengue disease caused by any serotype in individuals four years of age and older in Europe.&nbsp;&nbsp;Dengue fever, also known as breakbone fever, is a mosquito-borne virus endemic in more than 125 countries. It is caused by four dengue viruses spread by the Aedes aegypti mosquito. As per the CDC, nearly 400 million cases of dengue fever occur across the globe every year. Dengue can lead to the severity of muscle spasms and joint pain, dandy fever, or seven-day fever because of the usual duration of symptoms. It is observed that the <a href=\"https:\/\/www.delveinsight.com\/report-store\/dengue-fever-market\"><strong>incidence of dengue<\/strong><\/a> has increased globally over the past two decades and is a leading cause of fever among travelers returning from Latin America, the Caribbean, and Southeast Asia.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop and market an oral therapy for the treatment of [&hellip;]<\/p>\n","protected":false},"author":17,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[127,137,159,719,704,258,349,365,420,979,1111,639,5789],"industry":[17225],"therapeutic_areas":[],"class_list":["post-19943","post","type-post","status-publish","format-standard","hentry","category-notizia","tag-breast-cancer","tag-cancer","tag-cervical-cancer","tag-chronic-obstructive-pulmonary-disease","tag-fda","tag-gene-therapy","tag-latest-pharma-news","tag-lung-cancer","tag-news","tag-non-small-cell-lung-cancer-nsclc","tag-nsclc","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | AstraZeneca, Regeneron, Tenaya, Daiichi, C4X Discovery<\/title>\n<meta name=\"description\" content=\"C4X, AZs Signs Deal; Spectrum\u2019s Poziotinib; Tenaya\u2019s Gene Therapy; Regeneron\u2019s Libtayo; Japan Approves Trastuzumab Deruxtecan; Poziotinib...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | AstraZeneca, Regeneron, Tenaya, Daiichi, C4X Discovery\" \/>\n<meta property=\"og:description\" content=\"C4X, AZs Signs Deal; Spectrum\u2019s Poziotinib; Tenaya\u2019s Gene Therapy; Regeneron\u2019s Libtayo; Japan Approves Trastuzumab Deruxtecan; Poziotinib...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-29T12:26:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-11T12:09:52+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | AstraZeneca, Regeneron, Tenaya, Daiichi, C4X Discovery","description":"C4X, AZs Signs Deal; Spectrum\u2019s Poziotinib; Tenaya\u2019s Gene Therapy; Regeneron\u2019s Libtayo; Japan Approves Trastuzumab Deruxtecan; Poziotinib...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya","og_locale":"en_US","og_type":"article","og_title":"Pharma News | AstraZeneca, Regeneron, Tenaya, Daiichi, C4X Discovery","og_description":"C4X, AZs Signs Deal; Spectrum\u2019s Poziotinib; Tenaya\u2019s Gene Therapy; Regeneron\u2019s Libtayo; Japan Approves Trastuzumab Deruxtecan; Poziotinib...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-11-29T12:26:59+00:00","article_modified_time":"2023-12-11T12:09:52+00:00","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya","name":"Pharma News | AstraZeneca, Regeneron, Tenaya, Daiichi, C4X Discovery","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2022-11-29T12:26:59+00:00","dateModified":"2023-12-11T12:09:52+00:00","author":{"@id":""},"description":"C4X, AZs Signs Deal; Spectrum\u2019s Poziotinib; Tenaya\u2019s Gene Therapy; Regeneron\u2019s Libtayo; Japan Approves Trastuzumab Deruxtecan; Poziotinib...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-astrazeneca-regeneron-tenaya"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":""}]}},"author_meta":{"display_name":"","author_link":"https:\/\/www.delveinsight.com\/blog\/author"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cervical cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lung Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NSCLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cervical cancer<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Lung Cancer<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non-Small Cell Lung Cancer (NSCLC)<\/span>","<span class=\"advgb-post-tax-term\">NSCLC<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Nov 29, 2022","modified":"Updated on Dec 11, 2023"},"absolute_dates_time":{"created":"Posted on Nov 29, 2022 5:56 pm","modified":"Updated on Dec 11, 2023 5:39 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19943"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19943\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19943"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19943"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}